Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protectin...

Full description

Bibliographic Details
Main Authors: Anthony T. P. Chan, Sydney C. W. Tang
Format: Article
Language:English
Published: The Korean Society of Nephrology 2022-11-01
Series:Kidney Research and Clinical Practice
Subjects:
diabetic kidney disease
diabetic nephropathies
glucagon-like peptide-1 receptor agonist
non-steroidal mineralocorticoid receptor antagonist
selective endothelin receptor antagonist
sodium-glucose transporter 2 inhibitors
Online Access:http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf

Internet

http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf

Similar Items